Table 2—

Comparison of characteristics between high-risk and very-high-risk patients

High riskVery high riskP value*
Total cohort459191
Diabetes459 (100)191 (100)
Self-reported CVD0191 (100)
History of myocardial infarction0116 (60.7)
History of pulmonary vascular disease058 (30.4)
History of stroke or transient ischemic attack075 (39.3)
Diabetes at goal (HbA1c <7%)238 (51.9)104 (54.5)0.6
CVD risk factors
    Current cigarette smoking70 (15.3)29 (15.2)1
    Hypertension367 (80)168 (88)0.02
    HDL <40 mg/dl156 (34)79 (41.4)0.09
    Age ≥45 years (men), ≥55 years (women)383 (83.4)183 (95.8)<0.001
    Triglycerides ≥200 mg/dl145 (31.7)61 (32.1)0.9
LDL values and lipid drugs
    LDL <70 mg/dl37 (8.1)30 (15.7)0.005
No lipid drugs144
One lipid drug2122
Two or more lipid drugs24
    LDL 70–99 mg/dl170 (37)84 (44)0.1
No lipid drugs6623
One lipid drug9655
Two or more lipid drugs86
    LDL 100–129 mg/dl159 (34.6)53 (27.8)0.1
No lipid drugs8115
One lipid drug6932
Two or more lipid drugs96
    LDL 130–159 mg/dl66 (14.4)20 (10.5)0.2
No lipid drugs3911
One lipid drug256
Two or more lipid drugs23
    LDL >160 mg/dl27 (5.9)4 (2.1)0.04
No lipid drugs171
One lipid drug93
Two or more lipid drugs10
    Any dose of statin219 (47.7)130 (68.1)<0.001
    At least standard dose statin191 (41.6)110 (57.6)<0.001
  • Data are n (%).

  • *

    * P values obtained using Fisher’s exact test.

  • Standard dose is the dose required to achieve a 30–40% LDL reduction.